{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:29:08Z","timestamp":1748971748456},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T00:00:00Z","timestamp":1452556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aminoglycosides for patients undergoing intermittent hemodialysis (<jats:styled-content style=\"fixed-case\">IHD<\/jats:styled-content>) have traditionally been dosed at half the normal dose administered at the end of a hemodialysis session. Several investigations have suggested that administering higher doses preceding or with the initiation of dialysis would more readily optimize pharmacodynamic parameters. However, the selection of an optimal aminoglycoside dosing strategy in patients receiving <jats:styled-content style=\"fixed-case\">IHD<\/jats:styled-content> is complex and requires consideration of numerous factors, precluding a singular approach. By reviewing aminoglycoside pharmacokinetics, pharmacodynamics, risks for toxicity and resistance development, and practical considerations, we derive indication\u2010 and setting\u2010 specific recommendations. We identify some areas (definitive therapy of gram\u2010negative infections in patients receiving predictable hemodialysis sessions, for example) where dosing preceding or with the initiation of dialysis is optimal and feasible, and others (gram\u2010positive synergy, unstable patients with poor\/unpredictable vascular access) where postdialysis dosing remains preferred. Finally, given the dearth of data exploring the pharmacodynamics and clinical outcomes of <jats:styled-content style=\"fixed-case\">IHD<\/jats:styled-content> patients receiving aminoglycoside therapy, we identify several key questions in need of investigation.<\/jats:p>","DOI":"10.1111\/sdi.12458","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T14:30:59Z","timestamp":1452609059000},"page":"204-213","source":"Crossref","is-referenced-by-count":10,"title":["Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View"],"prefix":"10.1111","volume":"29","author":[{"given":"Gregory A.","family":"Eschenauer","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon W.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc7119"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv205"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G064"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q403"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2008.00554.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286902"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2012.655774"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02920707"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292987"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01762-12"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018020-00002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00222-10"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2008.00541.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70347-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01600407"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.1.93"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.623"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/520991"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.165564"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1591-1593.2002"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-05"},{"key":"e_1_2_8_24_1","first-page":"v","volume-title":"Clinical and Laboratory Standards Institute: [document]","author":"Clinical and Laboratory Standards Institute","year":"2005"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.4.2.120"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00088-7"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.20.1479.34476"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106758"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161060-00001"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.914"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1054"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.1.7"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/157.2.287"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597020-000000000-00000"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.suppl_C.29"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.16.1252.30876"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1549"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0031-0"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002295"},{"key":"e_1_2_8_41_1","volume-title":"Evidence\u2010Based Systematic Review: Drug\u2010Induced Hearing Loss\u2014Gentamicin","author":"Frymark T","year":"2010"},{"key":"e_1_2_8_42_1","volume-title":"Evidence\u2010Based Systematic Review: Drug\u2010Induced Hearing Loss\u2014Tobramycin","author":"Frymark T","year":"2010"},{"key":"e_1_2_8_43_1","volume-title":"Evidence\u2010Based Systematic Review: Drug\u2010Induced Hearing Loss\u2014Amikacin","author":"Frymark T","year":"2010"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2011.05.008"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2012.01090.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc053428"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00430107"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsdi.12458","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sdi.12458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:33:53Z","timestamp":1696206833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sdi.12458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,12]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/sdi.12458"],"URL":"https:\/\/doi.org\/10.1111\/sdi.12458","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,12]]}}}